Movement Alert｜WuXi Biologics Rises 3.27% in Regular Trading, Sustained Buybacks and CXO Sector Momentum Drive Stock Higher

Market Focus06-25

On June 25, WuXi Biologics rose 3.27% in regular trading, trading at HKD 33.34/share, with turnover of HKD 325 million.

On the news front, the company has conducted consecutive buybacks over recent sessions, repurchasing approximately 6.465 million shares between June 18 and June 23, spending around HKD 199 million. Year-to-date, the company has executed 14 buybacks totaling 34.218 million shares at a cumulative cost of HKD 1.072 billion, signaling management confidence in intrinsic value.

Meanwhile, WuXi-affiliated enterprises have announced a combined maximum buyback scale of RMB 5.5 billion. The broader CXO sector extended its rally, supported by innovative drug valuations at historical lows, recovering industry investment and financing activity, and strong overseas drug licensing momentum. Within the Life Sciences Tools and Services sector, Insilico rose 12.7%, WuXi XDC rose 4.51%, and WuXi AppTec rose 3.6%, demonstrating significant sector resonance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113758888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 11:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113758888","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi Biologics Rises 3.27% in Regular Trading, Sustained Buybacks and CXO Sector Momentum Drive Stock Higher","media":"Market Focus","content":"<p><p>On June 25, WuXi Biologics rose 3.27% in regular trading, trading at HKD 33.34/share, with turnover of HKD 325 million.</p><p>On the news front, the company has conducted consecutive buybacks over recent sessions, repurchasing approximately 6.465 million shares between June 18 and June 23, spending around HKD 199 million. Year-to-date, the company has executed 14 buybacks totaling 34.218 million shares at a cumulative cost of HKD 1.072 billion, signaling management confidence in intrinsic value.</p><p>Meanwhile, WuXi-affiliated enterprises have announced a combined maximum buyback scale of RMB 5.5 billion. The broader CXO sector extended its rally, supported by innovative drug valuations at historical lows, recovering industry investment and financing activity, and strong overseas drug licensing momentum. Within the Life Sciences Tools and Services sector, Insilico rose 12.7%, WuXi XDC rose 4.51%, and WuXi AppTec rose 3.6%, demonstrating significant sector resonance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi Biologics Rises 3.27% in Regular Trading, Sustained Buybacks and CXO Sector Momentum Drive Stock Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi Biologics Rises 3.27% in Regular Trading, Sustained Buybacks and CXO Sector Momentum Drive Stock Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 11:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, WuXi Biologics rose 3.27% in regular trading, trading at HKD 33.34/share, with turnover of HKD 325 million.</p><p>On the news front, the company has conducted consecutive buybacks over recent sessions, repurchasing approximately 6.465 million shares between June 18 and June 23, spending around HKD 199 million. Year-to-date, the company has executed 14 buybacks totaling 34.218 million shares at a cumulative cost of HKD 1.072 billion, signaling management confidence in intrinsic value.</p><p>Meanwhile, WuXi-affiliated enterprises have announced a combined maximum buyback scale of RMB 5.5 billion. The broader CXO sector extended its rally, supported by innovative drug valuations at historical lows, recovering industry investment and financing activity, and strong overseas drug licensing momentum. Within the Life Sciences Tools and Services sector, Insilico rose 12.7%, WuXi XDC rose 4.51%, and WuXi AppTec rose 3.6%, demonstrating significant sector resonance.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1113758888","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113758888","pubTimestamp":1782356985,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, WuXi Biologics rose 3.27% in regular trading, trading at HKD 33.34/share, with turnover of HKD 325 million.On the news front, the company has conducted consecutive buybacks over recent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"动向提示|药明生物常规交易涨3.27%持续回购和CXO板块动能推动股价走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On June 25, WuXi Biologics rose 3.27% in regular trading, trading at HKD 33.34/share, with turnover of HKD 325 million.On the news front, the company has conducted consecutive buybacks over recent sessions, repurchasing approximately 6.465 million shares between June 18 and June 23, spending around HKD 199 million. Year-to-date, the company has executed 14 buybacks totaling 34.218 million shares at a cumulative cost of HKD 1.072 billion, signaling management confidence in intrinsic value.Meanwhile, WuXi-affiliated enterprises have announced a combined maximum buyback scale of RMB 5.5 billion. The broader CXO sector extended its rally, supported by innovative drug valuations at historical lows, recovering industry investment and financing activity, and strong overseas drug licensing momentum. Within the Life Sciences Tools and Services sector, Insilico rose 12.7%, WuXi XDC rose 4.51%, and WuXi AppTec rose 3.6%, demonstrating significant sector resonance.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113758888","isCrawlerRequest":true}